KYNTRA BIO, INC. (KYNB) earnings date, results and what the price requires
Nasdaq · SEC CIK 0000921299 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 13, 2026 | $-1.5M | $12.0M | $2.96 | Filing |
| Mar 31, 2026 | May 11, 2026 | $3.7M | $-15.2M | $-3.76 | Filing |
| Dec 31, 2025 | Mar 16, 2026 | $1.3M | $-14.2M | $-3.51 | Filing |
| Sep 30, 2025 | Nov 10, 2025 | $1.1M | $200.6M | $49.61 | Filing |
| Jun 30, 2025 | Aug 11, 2025 | $1.3M | $-7.6M | $-1.88 | Filing |
| Mar 31, 2025 | May 12, 2025 | $2.7M | $4.6M | $1.15 | Filing |
| Dec 31, 2024 | Feb 20, 2025 | $3.1M | $18.0M | $-3.42 | Filing |
| Sep 30, 2024 | Nov 12, 2024 | $123,000 | $-17.1M | $-4.25 | Filing |
What would KYNTRA BIO, INC. have to report for its valuation to change?
At $5.36, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -60.1% a year, to $0.46. On that path the next quarter needs diluted EPS near $19.79, against $49.61 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -60.1% | -60.1% |
| EPS needed in final year | $0.46 | $0.46 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. KYNB goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.